Dynavax Technologies Corp. (NASDAQ:DVAX) shares were up 4.9% during mid-day trading on Friday . The company traded as high as $16.75 and last traded at $16.73, with a volume of 626,684 shares trading hands. The stock had previously closed at $15.95.

Several research analysts have issued reports on the stock. Zacks Investment Research cut shares of Dynavax Technologies Corp. from a “hold” rating to a “sell” rating in a report on Tuesday, April 19th. JPMorgan Chase & Co. cut shares of Dynavax Technologies Corp. from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $29.00 to $22.00 in a report on Wednesday, April 27th. Royal Bank Of Canada cut shares of Dynavax Technologies Corp. from an “outperform” rating to a “sector perform” rating and decreased their target price for the stock from $48.00 to $17.00 in a report on Wednesday, April 27th. Finally, Cowen and Company reaffirmed a “buy” rating and issued a $60.00 target price on shares of Dynavax Technologies Corp. in a report on Thursday, April 28th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $32.20.

The company’s market capitalization is $644.02 million. The company has a 50 day moving average price of $14.98 and a 200 day moving average price of $17.62.

Dynavax Technologies Corp. (NASDAQ:DVAX) last posted its quarterly earnings results on Friday, August 5th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.68) by $0.07. The firm had revenue of $2.65 million for the quarter, compared to analysts’ expectations of $1.58 million. During the same quarter in the previous year, the firm posted ($0.80) EPS. The company’s revenue was up 70.8% on a year-over-year basis. Equities research analysts anticipate that Dynavax Technologies Corp. will post ($2.90) EPS for the current fiscal year.

In related news, CEO Eddie Gray purchased 2,750 shares of the business’s stock in a transaction dated Friday, May 20th. The shares were purchased at an average cost of $15.57 per share, for a total transaction of $42,817.50. Following the completion of the acquisition, the chief executive officer now owns 5,050 shares in the company, valued at approximately $78,628.50. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Several hedge funds and institutional investors recently bought and sold shares of the company. Swiss National Bank boosted its position in Dynavax Technologies Corp. by 5.7% in the fourth quarter. Swiss National Bank now owns 48,528 shares of the biopharmaceutical company’s stock worth $1,172,000 after buying an additional 2,600 shares during the last quarter. California State Teachers Retirement System boosted its position in shares of Dynavax Technologies Corp. by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 67,895 shares of the biopharmaceutical company’s stock valued at $1,640,000 after buying an additional 1,177 shares during the last quarter. Finally, Trexquant Investment LP boosted its position in shares of Dynavax Technologies Corp. by 14.5% in the fourth quarter. Trexquant Investment LP now owns 70,200 shares of the biopharmaceutical company’s stock valued at $1,696,000 after buying an additional 8,911 shares during the last quarter.

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.